Trial Profile

A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talquetamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Janssen Pharmaceutical KK

Most Recent Events

20 Nov 2024 According to Johnson & Johnson media release, the company has submitted an application for manufacturing and marketing approval of toarquetamab for relapsed or refractory multiple myeloma. Filing is based on results from the Phase I/II MonumenTAL -1 study2,3 and the Phase I MMY1003 study4.
14 Aug 2024 Planned End Date changed from 14 Aug 2024 to 14 Aug 2025.
27 Feb 2024 Planned End Date changed from 31 Dec 2024 to 14 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com